| Machine learning–based liquid biomarker analysis from the NEONAX trial for response prediction to perioperative (PO) and adjuvant (A) gemcitabine/nab-paclitaxel in resectable PDAC (rPDAC). |
Seufferlein T |
Ettrich T |
| J Clin Oncol 43 (no.4_suppl.): 755 |
Abstract |
2025 |
|
Pankreaskarzinom
|
NEONAX |
AIO-PAK-0313 |
| ascopubs.org/doi/10.1200/JCO.2025.43.4_suppl.75 |
|
|
| Prognostic and predictive impact of the baseline systemic proteome in patients with RAS wild-type metastatic colorectal cancer: Analysis from the randomized phase II PanaMa (AIO KRK0212) trial. |
Ballhausen A |
Modest D |
| J Clin Oncol 43 (no. 16_suppl): 3546 |
Abstract |
2025 |
|
Kolon-/Rektum-/Dünndarmtumoren
|
PanaMa |
AIO-KRK-0212 |
| ascopubs.org/doi/10.1200/JCO.2025.43.16_suppl.3546 |
|
|
| Randomized trial of standard chemotherapy alone or combined with atezolizumab as adjuvant therapy for patients with stage III deficient DNA mismatch repair (dMMR) colon cancer (Alliance A021502; ATOMIC). |
Sinicrope F |
Meyerhardt J |
| J Clin Oncol 43 (no. 17_suppl): LBA1 |
Abstract |
2025 |
|
Kolon-/Rektum-/Dünndarmtumoren
|
ATOMIC |
AIO-KRK-0317 |
| ascopubs.org/doi/10.1200/JCO.2025.43.17_suppl.LBA1 |
|
|
| Five-year outcomes of perioperative or only adjuvant gemcitabine plus nab-paclitaxel for resectable pancreatic cancer (the NEONAX trial): A randomized phase II trial of the AIO pancreatic cancer group |
Ettrich T |
Seufferlein T |
| J Clin Oncol 43 (no. 16_suppl): 4193 |
Abstract |
2025 |
|
Pankreaskarzinom
|
NEONAX |
AIO-PAK-0313 |
| ascopubs.org/doi/10.1200/JCO.2025.43.16_suppl.4193 |
|
|
| Impact of anti-EGFR and anti-VEGF antibodies on survival in BRAFV600E mutated metastatic colorectal cancer: A pooled analysis of eight clinical trials performed in the first-line treatment of mCRC (German AIO Study Group). |
Weiss L |
Heinemann V |
| J Clin Oncol 43 (no. 16_suppl): 3543 |
Abstract |
2025 |
|
Kolon-/Rektum-/Dünndarmtumoren
|
|
|
| ascopubs.org/doi/10.1200/JCO.2025.43.16_suppl.3543 |
|
|
| Neotrace: A multicenter phase II study of neoadjuvant sacituzumab govitecan plus zimberelimab followed by adjuvant zimberelimab with or without sacituzumab govitecan in patients with resectable non-small cell lung cancer |
Althoff F |
Sebastian M |
| J Clin Oncol 43 (no. 16_suppl): TPS8120 |
Abstract |
2025 |
|
Thorakale Onkologie
|
NeoTRACE |
AIO-TRK/YMO-0224 |
| ascopubs.org/doi/10.1200/JCO.2025.43.16_suppl.TPS8120 |
|
|
| A PBMC and machine learning based biomarker signature to predict second line chemotherapy success in advanced PDAC: Translational data of the PREDICT trial—A prospective, multicenter, trial of the AIO Pancreatic Cancer Group (AIO-PAK-0216). |
Lahusen A |
Ettrich T |
| J Clin Oncol 43 (no. 16_suppl): 4187 |
Abstract |
2025 |
|
Pankreaskarzinom
|
PREDICT |
AIO-PAK-0216 |
| ascopubs.org/doi/10.1200/JCO.2025.43.16_suppl.4187 |
|
|
| Serum and tumor immune cell distribution as predictor of response to immune checkpoint blockade in solid tumors. |
Dreikhausen L |
Ebert M |
| J Clin Oncol 43 (no. 16_suppl): e16029 |
Abstract |
2025 |
| ascopubs.org/doi/10.1200/JCO.2025.43.16_suppl.e16029 |
|
|
| Assessing the predictive role of tumor sidedness in RAS and BRAF wild-type metastatic colorectal cancer (mCRC) treated with first-line doublets + anti-EGFRs/bevacizumab (bev) or triplet + bev: An individual patient data pooled analysis of 10 randomized clinical trials. |
Germani MM |
Cremolini C |
| J Clin Oncol 43 (no. 16_suppl): 3538 |
Abstract |
2025 |
|
Kolon-/Rektum-/Dünndarmtumoren
|
|
|
| ascopubs.org/doi/10.1200/JCO.2025.43.16_suppl.3538 |
|
|
| The prognostic and predictive role of HER2 amplification/overexpression and HER2 mutations in metastatic colorectal cancer treated with first-line chemotherapy plus bevacizumab/anti-EGFRs: An individual patient data pooled analysis of eight randomized trials |
Germani MM |
Cremolini C |
| J Clin Oncol 43 (no. 16_suppl): 3537 |
Abstract |
2025 |
|
Kolon-/Rektum-/Dünndarmtumoren
|
|
|
| ascopubs.org/doi/10.1200/JCO.2025.43.16_suppl.3537 |
|
|
